Publication

 

2019

 

Friedman, L., Smoum, R., Feldman, M., Mechoulam, R. and Steinberg, D. (2019). Does the Endocannabinoid Anandamide Affect Bacterial Quorum Sensing, Vitality, and Motility?. Cannabis and Cannabinoid Research, 4(2), pp.102-109.

Petrie, G., Wills, K., Piscitelli, F., Smoum, R., Limebeer, C., Rock, E., Humphrey, A., Sheppard-Perkins, M., Lichtman, A., Mechoulam, R., Di Marzo, V. and Parker, L. (2019). Oleoyl glycine: interference with the aversive effects of acute naloxone-precipitated MWD, but not morphine reward, in male Sprague–Dawley rats. Psychopharmacology, 236(9), pp.2623-2633.

 

Stark, T., Ruda-Kucerova, J., Iannotti, F., D'Addario, C., Di Marco, R., Pekarik, V., Drazanova, E., Piscitelli, F., Bari, M., Babinska, Z., Giurdanella, G., Di Bartolomeo, M., Salomone, S., Sulcova, A., Maccarrone, M., Wotjak, C., Starcuk, Z., Drago, F., Mechoulam, R., Di Marzo, V. and Micale, V. (2019). Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. Neuropharmacology, 146, pp.212-221.

Donvito, G., Piscitelli, F., Muldoon, P., Jackson, A., Vitale, R., D'Aniello, E., Giordano, C., Ignatowska-Jankowska, B., Mustafa, M., Guida, F., Petrie, G., Parker, L., Smoum, R., Sim-Selley, L., Maione, S., Lichtman, A., Damaj, M., Di Marzo, V. and Mechoulam, R. (2019). N-Oleoyl-glycine reduces nicotine reward and withdrawal in mice. Neuropharmacology, 148, pp.320-331.

 

Mechoulam, R. ed., 2019. Cannabinoids as therapeutic agents. CRC Press.

 

Magid, L., Heymann, S., Elgali, M., Avram, L., Cohen, Y., Liraz-Zaltsman, S., Mechoulam, R. and Shohami, E. (2019). Role of CB2 Receptor in the Recovery of Mice after Traumatic Brain Injury. Journal of Neurotrauma, 36(11), pp.1836-1846.

 

Hirsch S, Tam J (2019) Cannabis: From a Plant That Modulates Feeding Behaviors toward Developing Selective Inhibitors of the Peripheral Endocannabinoid System for the Treatment of Obesity and Metabolic Syndrome. Toxins, 11(5): 275.

Aran A, Eylon M, Harel M, Polianski L, Nemirovski A, Tepper S, Schnapp A, Cassuto H, Wattad N, Tam J (2019) Lower Circulating Endocannabinoid Levels in Children with Autism Spectrum Disorder. Mol Autism, 10:2.

 

Hinden L, Tam J (2019) Do Endocannabinoids Regulate Glucose Reabsorption in the Kidney? Nephron,11:1-4.

 

Baraghithy S, Smoum R, Drori A, Hadar R, Gammal A, Hirsch S, Attar-Namdar M, Nemirovski A, Gabet Y, Langer Y, Pollak Y, Schaaf CP, Rech ME, Gross-Tsur V, Bab I, Mechoulam RTam J (2019) Magel2 Modulates Bone Remodeling and Mass in Prader Willi Syndrome by Affecting Oleoyl Serine Levels and Activity. J Bone Miner Res. 34:93-105.

 

​Azar S, Sherf-Dagan S, Nemirovski A, Webb M, Raziel A, Keidar A, Goitein D, Sakran N, Shibolet O, Tam J, Zelber-Sagi S (2019) Circulating Endocannabinoids Are Reduced Following Bariatric Surgery and Associated with Improved Metabolic Homeostasis in Humans. Obes Surg29:268-276.

 

Drori A, Permyakova A, Hadar R, Udi S, Nemirovski A, Tam J (2019) Cannabinoid-1 Receptor Regulates Mitochondrial Dynamics and Function in Renal Proximal Tubular Cells. Diabetes Obes Metab. 21:146-159.

 

 

2018

 

Zachut M, Kra G, Moallem U, Livshitz L, Levin Y, Udi S, Nemirovski A, Tam J (2018) Characterization of the Endocannabinoid System in Subcutaneous Adipose Tissue in Periparturient Dairy Cows and its Association to Metabolic Profiles. PLoS One., 13:e0205996.

 

Ganot N, Braitbard O, Gammal A, Tam J, Hochman J, Tshuva EY (2018) In Vivo Anticancer Activity of a Non‐Toxic Inert Phenolato Ti Complex: High Efficacy on Solid Tumors Alone and Combined with Pt Drugs. Chem Med Chem. 13:2290-2296.

 

Deis S, Srivastava RK, de Azua IR, Bindila L, Baraghithy S, Lutz B, Bab I, Tam J (2018) Age-related regulation of bone formation by the sympathetic cannabinoid CB1 receptor. Bone 108:34-42.

 

Hinden L, Udi S, Drori A, Gammal A, Nemirovski A, Hadar R, Baraghithy S, Permyakova A, Geron M, Cohen M, Tsytkin-Kirschenzweig S, Riahi Y, Leibowitz G, Nahmias Y, Priel ATam J (2018) Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic Nephropathy. J Am Soc Nephrol, 29:434-448.

 

Azar S, Sherf-Dagan S, Nemirovski A, Webb M, Raziel A, Keidar A, Goitein D, Sakran N, Shibolet O, Tam J, Zelber-Sagi S (2018) Circulating Endoannabinoids Are Reduced Following Bariatric Surgery and Associated with Improved Metabolic Homeostasis in Humans. Obes Surg. doi: 10.1007/s11695-018-3517-0.  

 

Drori A, Permyakova A, Hadar R, Udi S, Nemirovski A, Tam J (2018) Cannabinoid-1 receptor regulates mitochondrial dynamics and function in renal proximal tubular cells. Diabetes Obes Metab. doi: 10.1111/dom.13497.

 

 

Hen-Shoval D, Amar S, Shbiro L, Smoum R, Haj CG, Mechoulam R, Zalsman G, Weller A, Shoval G (2018) Acute oral cannabidiolic acid methyl ester reduces depression-like behavior in two genetic animal models of depression. Behav Brain Res. 351:1-3.

 

Chiurchiù V, Leuti A, Smoum R, Mechoulam R, Maccarrone M (2018) Bioactive lipids ALIAmides differentially modulate inflammatory responses of distinct subsets of primary human T lymphocytes. FASEB J. doi: 10.1096/fj.201800107R.

 

 

Ibera C, Shalom B, Saifi F, Shruder J, Davidson E (2018) Effects of cannabis extract premedication on anesthetic depth. Harefuah. 157(3):162-166.

 

Abuhasira R, Schleider LB, Mechoulam R, Novack V (2018) Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Intern Med. 49:44-50.

 

Bar-Lev Schleider L, Mechoulam R, Lederman V, Hilou M, Lencovsky O, Betzalel O, Shbiro L, Novack V (2018) Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med. 49:37-43.

 

Tam J, Hinden L, Drori A, Udi S, Azar S, Baraghithy S (2018) The therapeutic potential of targeting the peripheral endocannabinoid/CB1 receptor system. Eur J Intern Med. 49:23-29.

 

2017

 

Bilkei-Gorzo A, Albayram O, Draffehn A, Michel K, Piyanova A, Oppenheimer H, Dvir-Ginzberg M, Racz I, Ulas T, Imbeault S, Bab I, Schultze JL, Zimmer A (2017) A chronic low dose of Δ9-tetrahydrcannabinol (THC) restores cognitive function in old mice. Nat Med. 23(6):782-787.

 

Atsmon J, Cherniakov I, Izgelov D, Hoffman A, Domb AJ, Deutsch L, Deutsch F, Heffetz D, Sacks H (2017) PTL401, a New Formulation Based on Pro-nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers. J Pharm Sci. 107(5):1423-1429.

 

Pertwee RG, Rock EM, Guenther K, Limebeer CL, Stevenson LA, Haj C, Smoum R, Parker LA, Mechoulam R (2017) Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats. Br J Pharmacol. 175(1):100-112.

 

Hinden L, Udi S, Drori A, Gammal A, Nemirovski A, Hadar R, Baraghithy S, Permyakova A, Geron M, Cohen M, Tsytkin-Kirschenzweig S, Riahi Y, Leibowitz G, Nahmias Y, Priel A, Tam J (2017) Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic Nephropathy. J Am Soc Nephrol. 29(2):434-448.

 

Silva NR, Gomes FV, Fonseca MD, Mechoulam R, Breuer A, Cunha TM, Guimarães FS (2017) Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative. Prog Neuropsychopharmacol Biol Psychiatry. 79(Pt B):369-377. 

 

Wang Y, Mukhopadhyay P, Cao Z, Wang H, Feng D, Haskó G, Mechoulam R, Gao B, Pacher P (2017) Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury. Sci Rep. 7(1):12064. 

 

Cherniakov I, Izgelov D, Barasch D, Davidson E, Domb AJ, Hoffman A (2017) Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration. J Control Release. 266:1-7.

 

Cherniakov I, Izgelov D, Domb AJ, Hoffman A (2017) The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta- 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model. Eur J Pharm Sci. 109:21-30.

 

Udi S, Hinden L, Earley B, Drori A, Reuveni N, Hadar R, Cinar R, Nemirovski A, Tam J (2017) Proximal Tubular Cannabinoid-1 Receptor Regulates Obesity-induced Chronic Kidney Disease. J Am Soc Nephrol. 28(12):3518-3532. 


Tam J, Szanda G, Drori A, Liu Z, Cinar R, Kashiwaya Y, Reitman ML, Kunos G (2017) Peripheral Cannabinoid-1 Receptor Blockade Restores Hypothalamic Leptin Signaling. Mol Metab. 6(10):1113-1125.


Zelber-Sagi S, Azar S, Nemirovski A, Webb M, Halpern Z, Shibolet O, Tam J (2017) Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease. Obesity. 25(1):94-101.


Mechoulam R (2017) Cannabis and epilepsy. Epilepsy Behav. 70(Pt B):278-279.


Rock EM, Limebeer CL, Petrie GN, Williams LA, Mechoulam R, Parker LA (2017) Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats. Psychopharmacology (Berl) 234(14):2207-2217.

 

2016

Lee WS, Erdelyi K, Matyas C, Mukhopadhyay P, Varga ZV, Liaudet L, Haskó G, Čiháková D, Mechoulam R, Pacher P (2016) Cannabidiol limits T cell-mediated chronic autoimmune myocarditis: implications to autoimmune disorders and organ transplantation. Mol Med. 22:136-146.


Kozela E, Haj C, Hanuš L, Chourasia M, Shurki A, Juknat A, Kaushansky N, Mechoulam R, Vogel Z (2016) HU-446 and HU-465, Derivatives of the Non-psychoactive Cannabinoid Cannabidiol, Decrease the Activation of Encephalitogenic T Cells. Chem Biol Drug Des. 87(1):143-53.


Shoval G, Shbiro L, Hershkovitz L, Hazut N, Zalsman G, Mechoulam R, Weller A (2016) Prohedonic Effect of Cannabidiol in a Rat Model of Depression. Neuropsychobiology. 73(2):123-9.


Fisher T, Golan H, Schiby G, PriChen S, Smoum R, Moshe I, Peshes-Yaloz N, Castiel A, Waldman D, Gallily R, Mechoulam R, Toren A (2016) In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma. Curr Oncol. 23(2):S15-22.


Tam J (2016) The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases. J Basic Clin Physiol Pharmacol. 27(3):267-76.


Mann A, Cohen-Yeshurun A, Trembovler V, Mechoulam R, Shohami E (2016) Are the endocannabinoid-like compounds N-acyl aminoacids neuroprotective after traumatic brain injury? J Basic Clin Physiol Pharmacol. 27(3):209-16.


Juknat A, Kozela E, Kaushansky N, Mechoulam R, Vogel Z (2016) Anti-inflammatory effects of the cannabidiol derivative dimethylheptyl-cannabidiol - studies in BV-2 microglia and encephalitogenic T cells. J Basic Clin Physiol Pharmacol. 27(3):289-96.


Maslov LN, Khaliulin I, Zhang Y, Krylatov AV, Naryzhnaya NV, Mechoulam R, De Petrocellis L, Downey JM (2016) Prospects for Creation of Cardioprotective Drugs Based on Cannabinoid Receptor Agonists. J Cardiovasc Pharmacol Ther. 21(3):262-72.


Mechoulam R (2016) Cannabis - the Israeli perspective. J Basic Clin Physiol Pharmacol. 27(3):181-7.


Shohami E, Horowitz M. Cannabinoids in Health and Disease (2016) J Basic Clin Physiol Pharmacol. 27(3):175-9.


Breuer A, Haj CG, Fogaça MV, Gomes FV, Silva NR, Pedrazzi JF, Del Bel EA, Hallak JC, Crippa JA, Zuardi AW, Mechoulam R, Guimarães FS (2016) Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects. PLoS One. 11(7):e0158779.


Rock EM, Boulet N, Limebeer CL, Mechoulam R, Parker LA (2016) Cannabinoid 2 (CB2) receptor agonism reduces lithium chloride-induced vomiting in Suncus murinus and nausea-induced conditioned gaping in rats. Eur J Pharmacol. 786:94-9.


Knani I, Earley BJ, Udi S, Nemirovski A, Hadar R, Gammal A, Cinar R, Hirsch HJ, Pollak Y, Gross I, Eldar-Geva T, Reyes-Capo DP, Han JC, Haqq AM, Gross-Tsur V, Wevrick R, Tam J (2016) Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome. Mol Metab. 5(12):1187-1199.


Haroutounian S, Ratz Y, Ginosar Y, Furmanov K, Saifi F, Meidan R, Davidson E (2016) The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain: A Prospective Open-label Study. Clin J Pain. 32(12):1036-1043.